• * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 3 result(s)
Country
The RAMEDIS system is a platform independent, web-based information system for rare metabolic diseases based on filed case reports. It was developed in close cooperation with clinical partners to allow them to collect information on rare metabolic diseases with extensive details, e.g. about occurring symptoms, laboratory findings, therapy and molecular data.
Content type(s)
Country
<<<!!!<<< This product is in the archive and is no longer current. >>>!!!>>> Biobanks are a key prerequisite for modern medical research. By linking samples and clinical data they make it possible to clarify the causes and the course of diseases. The German Biobank Registry pools the medically relevant biobanks in Germany. The German Biobank Registry provides an overview of the medical biobanks in Germany; increases the international visibility of German biobanks; facilitates the networking of biobanks; promotes an exchange of information and samples between research teams; supports the use of existing resources; provides information for investments in biobanks and promotes transparency and trust in research where human samples are used. Searching for samples in all biobanks is possible at the project portal (P2B2) https://p2b2.fraunhofer.de/ after registration.
The PRO-ACT platform houses the largest ALS clinical trials dataset ever created. It is a powerful tool for biomedical researchers, statisticians, clinicians, or anyone else interested in "Big Data." PRO-ACT merges data from existing public and private clinical trials, generating an invaluable resource for the design of future ALS clinical trials. The database will also contribute to the identification of unique observations, novel correlations, and patterns of ALS disease progression, as well as a variety of still unconsidered analyses. More than 600,000 people around them world are battling ALS. The disease strikes indiscriminately, and typically patients will die within 2-5 years following diagnosis. Currently, there are no effective treatments or a cure for ALS. Users of PRO-ACT are helping to accelerate the discovery, development, and delivery of ALS treatments, which will provide hope to patients and their families.